Lisaftoclax (APG-2575)

Phase 3

ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Aug '27

AAPGPhase 3$6.4B

Lisaftoclax (APG-2575) Phase 3 Est. Readout

Lisaftoclax (APG-2575)• Relapsed/Refractory Acute Myeloid Leukaemia344

Aug 2027~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Relapsed/Refractory Acute Myeloid Leukaemia

View Full Landscape

Drug Information

Target Indication

Relapsed/Refractory Acute Myeloid Leukaemia

Clinical Trial

NCT04501120

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Azacitidine InjectionPhase 3

Higher-risk Myelodysplastic Syndrome

lisaftoclax +BTK inhibitorPhase 3

CLL/SLL

OlverembatinibPhase 3

GIST

AcalabrutinibPhase 3

CLL/SLL

BosutinibPhase 3

Chronic Myeloid Leukemia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts